Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency

Trial Profile

Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms EFFECT-HF
  • Sponsors Vifor
  • Most Recent Events

    • 12 Jul 2017 Results published in the Circulation
    • 07 Dec 2016 Results presented at the the American Heart Association's Scientific Sessions 2016, according to a Vifor Pharma media release.
    • 07 Dec 2016 Results published in a Vifor Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top